Pharmaceuticals Global On demand · 24-48h

Global Gelatin-Based Plasma Expander Market Strategic Research Report

Global Gelatin-Based Plasma Expander Market Strategic Resear…
$3,500 USD
Market Research Reports
Strategic Research Report
Global Gelatin-Based Plasma Expander Market
$1602025
12.1%CAGR
2032Forecast
Market Research Reports · Global
Market Research Reports Intelligence Series

By Type: Content of 4.0%, Content of 3.5%, Content of 3.2%

By Application: Preoperative Prevention, Cardiopulmonary Bypass and Dialysis

Regional Forecast: Asia Pacific, Latin America, MEA, Europe, North America

Key Players: Braun, Abbott, Wuhan Hualong Biological Pharmaceutical Co., Ltd., Zhejiang Kangle Pharmaceutical Co., Ltd., China BBCA Group Corporation, Harbin Sanctity Biological Pharmaceutical, Fuzhou Neptunus Futao Pharmaceuticals Co., Ltd., Dikang, WUHAN DOCAN PHARMACEUTICAL CO.LTD

Region: Global
Formats: PDF, Excel, Word & PowerPoint
Base year: 2025 · forecast to 2032
Length: 88 pages
Market size 2025
$160
Million USD
Forecast CAGR
12.1%
2025-2032
Forecast 2032
$355.9
Projected
Regionen
5
Asia Pacific · Latin America · MEA · Europe · North America

Übersicht

Scope of the Report

The global Gelatin-Based Plasma Expander market size is predicted to grow from US$ 160 million in 2025 to US$ 354 million in 2032; it is expected to grow at a CAGR of 12.1% from 2026 to 2032.

Plasma compatibilizer, also known as plasma compatibilizer, plasma substitute, it is a kind of colloidal solution with molecular weight close to the plasma protein, the effect of replacing and expanding the plasma capacity depends on its colloid osmotic pressure after input into the blood vessel.The global market for gelatin polypeptide plasma volume enhancers is highly concentrated. Before 2017, the output share of the nine major enterprises reached 93.72%, and the market scale was 94.71%.The top five enterprises in the market of gelatin polypeptide plasma compatibilizer are Braun medical, Abbott, Wuhan Hualong, Zhejiang Kangle and BBCA Group. Among them, Braun medical is firmly in the top spot, accounting for 46% of production in 2018.

Global Gelatin-Based Plasma Expander key players include Braun, Abbott, Wuhan Hualong Biological Pharmaceutical Co.,Ltd., etc. Global top three manufacturers hold a share over 80%.

China is the largest market, with a share over 30%, followed by Europe, and North America, both have a share over 50 percent.

In terms of product, Content of 4.0% is the largest segment, with a share over 45%. And in terms of application, the largest application is Preoperative Prevention, followed by Cardiopulmonary Bypass and Dialysis.

This report presents a comprehensive overview of the global Gelatin-Based Plasma Expander market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

  • Content of 4.0%
  • Content of 3.5%
  • Content of 3.2%

Segment by Application

  • Preoperative Prevention
  • Cardiopulmonary Bypass and Dialysis

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Gelatin-Based Plasma Expander market:

  • Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
  • Distributors, channel partners and end users in Preoperative Prevention, Cardiopulmonary Bypass and Dialysis evaluating demand and sourcing options
  • Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
  • Government agencies, industry associations and research institutions tracking industry developments and policy impact

Market snapshot

Global Gelatin-Based Plasma Expander Market Strategic Research Report snapshot, 2025–2032

Source: Market Research Reports
Market size CAGR 12.1%
Regional growth momentum
Market share by segment
Key metrics
Base value
$160
2025
Forecast
$355.9
2032
CAGR
12.1%
2025–2032
Regionen
5
global
Key companies
BraunAbbottWuhan Hualong Biological Pharmaceutical Co., Ltd.Zhejiang Kangle Pharmaceutical Co., Ltd.China BBCA Group CorporationHarbin Sanctity Biological PharmaceuticalFuzhou Neptunus Futao Pharmaceuticals Co., Ltd.Dikang
© MarketResearchReports.comDisclaimer: The actual data may vary in the final report which undergoes verification check post order confirmation.

Segments covered in this report

By Type
Content of 4.0%Content of 3.5%Content of 3.2%
By Application
Preoperative PreventionCardiopulmonary Bypass and Dialysis

Table of contents

Click a chapter to expand
01Executive Summary
02Industry Overview & Forecast
  • 2.1.1 Market Definition and Scope
  • 2.1.2 Market Size and Growth Forecast
  • 2.1.3 Volume Analysis
  • 2.1.4 Segment Outlook by Type
  • 2.1.5 Segment Outlook by Application
  • 2.1.6 Regional Outlook
  • 2.1.7 Structural Developments Shaping the Forecast
  • 2.1.8 Forecast Risks and Sensitivities
03Market Segmentation by Type
  • 3.1 Market Segmentation by Type
  • 3.1.1 Market by Type Overview
  • 3.1.2 Content of 4.0%
  • 3.1.3 Content of 3.5%
  • 3.1.4 Content of 3.2%
  • 3.1.5 Volume Analysis
04Market Segmentation by Application
  • 4.1 Market Segmentation by Application
  • 4.1.1 Market by Application Overview
  • 4.1.2 Preoperative Prevention
  • 4.1.3 Cardiopulmonary Bypass and Dialysis
  • 4.1.4 Volume Analysis
05Regional Market Forecast
  • Asia Pacific
  • North America
  • Europe
  • Middle East & Africa
  • Latin America
06Country-Level Market Forecast
  • 6.1 Asia Pacific
  • 6.1.1 China
  • 6.1.2 Japan
  • 6.1.3 Korea
  • 6.1.4 Southeast Asia
  • 6.1.5 India
  • 6.1.6 Australia
  • 6.1.7 Rest of Asia Pacific
  • 6.2 North America
  • 6.2.1 United States
  • 6.2.2 Canada
  • 6.2.3 Mexico
  • 6.2.4 Rest of North America
  • 6.3 Europe
  • 6.3.1 Germany
  • 6.3.2 France
  • 6.3.3 UK
  • 6.3.4 Italy
  • 6.3.5 Russia
  • 6.3.6 Rest of Europe
  • 6.4 Middle East & Africa
  • 6.4.1 Egypt
  • 6.4.2 South Africa
  • 6.4.3 Israel
  • 6.4.4 Turkey
  • 6.4.5 GCC Countries
  • 6.4.6 Rest of Middle East & Africa
  • 6.5 Latin America
  • 6.5.1 Brazil
  • 6.5.2 Rest of Latin America
07Growth Drivers & Inhibitors
  • 7.1 Growth Drivers & Inhibitors
  • 7.1.1 Section Overview
  • 7.1.2 Growth Drivers
  • 7.1.3 Growth Inhibitors
  • 7.1.4 Driver and Inhibitor Impact Assessment
  • 7.1.5 Analyst Perspective
08Key Company Profiles
  • 8.1 Braun
  • 8.1.1 Company Overview
  • 8.1.2 Key Products & Segments
  • 8.1.3 Financial Performance (2023–2025)
  • 8.1.4 Business Strategy
  • 8.1.5 SWOT Analysis
  • 8.1.6 Strategic Implications (2026–2032)
  • 8.2 Abbott
  • 8.2.1 Company Overview
  • 8.2.2 Key Products & Segments
  • 8.2.3 Financial Performance (2023–2025)
  • 8.2.4 Business Strategy
  • 8.2.5 SWOT Analysis
  • 8.2.6 Strategic Implications (2026–2032)
  • 8.3 Wuhan Hualong Biological Pharmaceutical Co.,Ltd.
  • 8.3.1 Company Overview
  • 8.3.2 Key Products & Segments
  • 8.3.3 Financial Performance (2023–2025)
  • 8.3.4 Business Strategy
  • 8.3.5 SWOT Analysis
  • 8.3.6 Strategic Implications (2026–2032)
  • 8.4 Zhejiang Kangle Pharmaceutical Co.,Ltd.
  • 8.4.1 Company Overview
  • 8.4.2 Key Products & Segments
  • 8.4.3 Financial Performance (2023–2025)
  • 8.4.4 Business Strategy
  • 8.4.5 SWOT Analysis
  • 8.4.6 Strategic Implications (2026–2032)
  • 8.5 China BBCA Group Corporation
  • 8.5.1 Company Overview
  • 8.5.2 Key Products & Segments
  • 8.5.3 Financial Performance (2023–2025)
  • 8.5.4 Business Strategy
  • 8.5.5 SWOT Analysis
  • 8.5.6 Strategic Implications (2026–2032)
  • 8.6 Harbin Sanctity Biological Pharmaceutical
  • 8.6.1 Company Overview
  • 8.6.2 Key Products & Segments
  • 8.6.3 Financial Performance (2023–2025)
  • 8.6.4 Business Strategy
  • 8.6.5 SWOT Analysis
  • 8.6.6 Strategic Implications (2026–2032)
  • 8.7 Fuzhou Neptunus Futao Pharmaceuticals Co.,Ltd.
  • 8.7.1 Company Overview
  • 8.7.2 Key Products & Segments
  • 8.7.3 Financial Performance (2023–2025)
  • 8.7.4 Business Strategy
  • 8.7.5 SWOT Analysis
  • 8.7.6 Strategic Implications (2026–2032)
  • 8.8 Dikang
  • 8.8.1 Company Overview
  • 8.8.2 Key Products & Segments
  • 8.8.3 Financial Performance (2023–2025)
  • 8.8.4 Business Strategy
  • 8.8.5 SWOT Analysis
  • 8.8.6 Strategic Implications (2026–2032)
  • 8.9 WUHAN DOCAN PHARMACEUTICAL CO.LTD
  • 8.9.1 Company Overview
  • 8.9.2 Key Products & Segments
  • 8.9.3 Financial Performance (2023–2025)
  • 8.9.4 Business Strategy
  • 8.9.5 SWOT Analysis
  • 8.9.6 Strategic Implications (2026–2032)
09Competitive Landscape
  • 9.1 Competitive Landscape Overview
  • 9.2 Competitive Intensity Assessment
  • 9.3 Key Player Strategies & Positioning
  • 9.4 Competitive Dynamics & Strategic Outlook
  • 9.4.1 Emerging Competitive Threats
  • 9.4.2 Consolidation vs. Fragmentation Outlook
  • 9.4.3 Competitive Response Matrix
  • 9.4.4 Strategic Recommendations, 2026–2032
10Porter's Five Forces Analysis
  • 10.1 Threat of New Entrants
  • 10.2 Bargaining Power of Buyers
  • 10.3 Bargaining Power of Suppliers
  • 10.4 Threat of Substitutes
  • 10.5 Competitive Rivalry
11PESTLE Analysis
  • 11.1 Political
  • 11.2 Economic
  • 11.3 Social and Demographic
  • 11.4 Technological
  • 11.5 Legal and Regulatory
  • 11.6 Environmental
  • 11.7 Strategic Implications of the PESTLE Assessment
12SWOT Analysis
13Future Trends & Outlook
  • 13.1 Future Trends & Outlook
  • 13.1.1 Trend Summary and Commercial Maturity Assessment
  • 13.1.2 Technology and Innovation Trends
  • 13.1.3 Long-Term Market Outlook
  • 13.1.4 Investment & M&A Activity Outlook
  • 13.1.5 Overall Outlook Assessment

Frequently asked questions

How big is the global Gelatin-Based Plasma Expander market?
The global Gelatin-Based Plasma Expander market is estimated at US$ 160 million in 2025 (base year) and is projected to reach US$ 354 million by 2032.
How fast is the Gelatin-Based Plasma Expander market expected to grow?
The market is expected to grow at a CAGR of 12.1% from 2026 to 2032, expanding from US$ 160 million in 2025 to US$ 354 million in 2032, roughly 2.2 times its base-year value.
What does the Gelatin-Based Plasma Expander market cover?
Plasma compatibilizer, also known as plasma compatibilizer, plasma substitute, it is a kind of colloidal solution with molecular weight close to the plasma protein, the effect of replacing and expanding the plasma capacity depends on its colloid osmotic pressure after input into the blood vessel.The global market for gelatin polypeptide plasma volume enhancers is highly concentrated. Among them, Braun medical is firmly in the top spot, accounting for 46% of production in 2018.
What are the main segments of the Gelatin-Based Plasma Expander market by type?
By type, the market is segmented into Content of 4.0%, Content of 3.5% and Content of 3.2%.
Which applications drive demand in the Gelatin-Based Plasma Expander market?
Key applications covered include Preoperative Prevention and Cardiopulmonary Bypass and Dialysis.
Who are the key players in the Gelatin-Based Plasma Expander market?
Key players profiled include Braun, Abbott, Wuhan Hualong Biological Pharmaceutical Co., Zhejiang Kangle Pharmaceutical Co., China BBCA Group Corporation, Harbin Sanctity Biological Pharmaceutical, Fuzhou Neptunus Futao Pharmaceuticals Co. and Dikang, among 9 companies covered in total.
Which regions and countries are covered for Gelatin-Based Plasma Expander?
The market is analysed across Asia Pacific, North America, Europe, Middle East & Africa and Latin America, with 20 country-level markets including China, Japan, United States, Canada, Germany, France, Egypt and South Africa.
Who should buy the Gelatin-Based Plasma Expander market report?
The report is intended for manufacturers and solution providers, distributors and end users in Preoperative Prevention and Cardiopulmonary Bypass and Dialysis, investors and consultants, and government or industry bodies who need market size, segmentation, competitive and regional data for the Gelatin-Based Plasma Expander market.
What license options are available for this report?
The report is available as a Single User License (US$ 3,500, one named user), a Site License (US$ 5,250, up to 10 users) and a Global / Corporate License (US$ 7,000, unlimited users), all delivered in PDF format.

Research Methodology

All MarketResearchReports.com strategic research reports follow a rigorous, multi-stage methodology combining AI-assisted data synthesis with expert analyst validation.

01
Secondary Research & Data Aggregation

Systematic collection from 500+ verified sources including SEC filings, industry databases (Bloomberg, Statista, OECD), regulatory filings, trade publications, patent databases, and company annual reports. AI-assisted extraction identifies relevant data points across 10,000+ documents per report.

02
Market Sizing — Bottom-Up & Top-Down

Dual-validation approach: bottom-up sizing aggregates segment-level production, consumption, and trade data; top-down sizing cross-validates against macroeconomic indicators and total addressable market estimates. Discrepancies >5% trigger analyst review.

03
Competitive Intelligence

Company profiles built from public financial disclosures, product launches, M&A activity, job postings (as capability proxies), and supply chain mapping. Market share estimates triangulated across revenue, capacity, and shipment data.

04
Demand Forecasting

CAGR projections use time-series regression on 5-10 years of historical data, adjusted for identified demand drivers (technology adoption curves, regulatory catalysts, demographic shifts) and demand inhibitors (cost barriers, substitution risk). Scenario modeling covers base, optimistic, and conservative cases.

05
Analyst Validation & Quality Assurance

All quantitative outputs reviewed by a domain-specialist analyst before publication. Data triangulation requires minimum 3 independent sources for every key figure. Reports undergo a structured peer review against our 47-point quality checklist covering methodology, data citations, logical consistency, and formatting standards.

06
Continuous Updates

On-demand reports are generated at time of purchase, incorporating the most recent available data. Static reports are republished when underlying market conditions shift by >10% from baseline assumptions. Purchasers receive update notifications for 12 months.

All data sources are cited within the report. View our full research methodology →
Select a license
from 3.500,00 $
Report License Type
Optional add-ons
On demand · delivered within 24-48 hours
Secure checkout · SSL encrypted
License terms included
Post-purchase analyst support
Custom research

Need a customized version?

Get country-, segment- or company-specific intelligence tailored to your exact requirements.

Request custom research →
Talk to a research advisor USA: +1-302-703-9904 India: +91-8762746600
Trusted by

Leading Brands in This Industry

Logos are trademarks of their respective owners and indicate a verified past business relationship, not a current partnership or endorsement.